Sarcopenia: revised European consensus on definition and diagnosis
Саркопения: пересмотренный европейский консенсус по определению и диагностике
2018-09-24
SCID: 54.1/b3dzpnt5
Discuss with AI
EWGSOP2 consensusmuscle quantity and qualitymuscle strengthphysical performancesarcopenia
Figures from the paper
Abstract (AI)
Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions: EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
Key Findings
1
EWGSOP2 provides clear measurement cut-offs and calls for earlier detection and treatment to reduce adverse health outcomes.
2
EWGSOP2 redefines sarcopenia as a muscle disease involving muscle failure rooted in adverse muscle changes accumulating throughout life.
3
Low muscle strength is established as the primary characteristic of sarcopenia, while low muscle quantity or quality confirms the diagnosis.
4
Poor physical performance indicates severe sarcopenia under the updated consensus definition.
5
The revised clinical algorithm supports sarcopenia case-finding, diagnosis, confirmation, and severity classification.
Research Object
Sarcopenia (age-related muscle disease characterized by low muscle strength, quantity/quality, and impaired physical performance)
Research Subject
The revised definition, diagnostic criteria, case-finding algorithm, severity classification, and measurement cut-off points for sarcopenia
Publication Details
Publication Date
2018-09-24
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest